Spruce BiosciencesSPRB -1.12%35 PB Ratio is 2.05 as of Jun. 24, 2026, which is 193% above its 10-year median of 0.70. GuruFocus rates SPRB with a GF Score™ of 35/100 and a GF Value™ of $4.08 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,233 Biotechnology companies, Spruce Biosciences ranks better than 62.04% on this metric.
The historical rank and industry rank for Spruce Biosciences's PB Ratio or its related term are showing as below:
SPRB'
s PB Ratio Range Over the Past 10 Years
Min: 0.17 Med: 0.7 Max: 18.15
Current: 2.05
During the past 8 years, Spruce Biosciences's highest PB Ratio was 18.15. The lowest was 0.17. And the median was 0.70.
SPRB's PB Ratio is ranked better than 62.04% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs SPRB: 2.05
During the past 12 months, Spruce Biosciences's average Book Value Per Share Growth Rate was -7.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -47.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -43.50% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Spruce Biosciences was -33.80% per year. The lowest was -47.80% per year. And the median was -47.60% per year.
Back to Basics: PB Ratio
Spruce Biosciences (NAS:SPRB) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Spruce Biosciences PB Ratio Related Terms
Spruce Biosciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Spruce Biosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Spruce Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spruce Biosciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spruce Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Spruce Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Spruce Biosciences (SPRB) has a PB Ratio of 2.05 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Spruce Biosciences and its competitors. This is 193% above median its historical median of 0.70. Over the past decade, Spruce Biosciences' PB Ratio has ranged from 0.17 to 18.15. According to the industry distribution chart, Spruce Biosciences ranks #468 out of 1233 companies in the Biotechnology industry, placing it in the top 38%.
Is Spruce Biosciences' PB Ratio too high?
Spruce Biosciences' current PB Ratio of 2.05 is 193% above median its 10-year median of 0.70. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 18.15. The Biotechnology industry median PB Ratio is 2.83. Spruce Biosciences' value of 2.05 is 27.6% below this industry median. Based on the distribution chart, Spruce Biosciences ranks #468 out of 1233 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Spruce Biosciences has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spruce Biosciences' PB Ratio compare to HURA and AGEN?
According to the Biotechnology industry distribution chart, Spruce Biosciences ranks #468 out of 1233 companies for PB Ratio. This puts Spruce Biosciences in the upper half of its industry. The industry median PB Ratio is 2.83. Spruce Biosciences' value of 2.05 is 27.6% below this benchmark. Historically, Spruce Biosciences' own PB Ratio has ranged from 0.17 to 18.15 over the past decade. While the company's 10-year median is 0.70 vs. the industry median of 2.83, Spruce Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spruce Biosciences's current PB Ratio of 2.05 is 27.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Spruce Biosciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spruce Biosciences's current PB Ratio is 2.05, which is 193% above median its own 10-year median of 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spruce Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Spruce Biosciences (SPRB) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.08, compared to a current price of $51.87 — trading 1171.3% above its estimated fair value. The current PB Ratio is 2.05, which is 193% above median its 10-year median of 0.70 and 27.6% below the Biotechnology industry median of 2.83. Spruce Biosciences' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Spruce Biosciences (SPRB), the current PB Ratio is 2.05 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spruce Biosciences (SPRB) Overvalued in 2026?
Based on GuruFocus' analysis, Spruce Biosciences stock appears to be overvalued.
The current stock price of $51.87 is trading 1171.3% above its estimated GF Value™ of $4.08.
GuruFocus considers Spruce Biosciences to be Significantly Overvalued.
Key valuation signals for SPRB:
PB Ratio: 2.05 (193% above median its 10-year median of 0.70)
GF Value™: $4.08 vs. price of $51.87 (1171.3% above fair value)
Industry Position: 27.6% below the Biotechnology median (#468 of 1233)
No single metric tells the full story. See the SPRB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
35GF Score
Get the complete analysis for SPRB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRB has been successfully added to your 
